AU2021347349A1 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation Download PDF

Info

Publication number
AU2021347349A1
AU2021347349A1 AU2021347349A AU2021347349A AU2021347349A1 AU 2021347349 A1 AU2021347349 A1 AU 2021347349A1 AU 2021347349 A AU2021347349 A AU 2021347349A AU 2021347349 A AU2021347349 A AU 2021347349A AU 2021347349 A1 AU2021347349 A1 AU 2021347349A1
Authority
AU
Australia
Prior art keywords
mitapivat
amount
pediatric subject
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021347349A
Other languages
English (en)
Inventor
Cheuk-Yui LEUNG
Eric Simone
Ophelia Qiping YIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of AU2021347349A1 publication Critical patent/AU2021347349A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021347349A 2020-09-25 2021-09-24 Pharmaceutical formulation Pending AU2021347349A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063083834P 2020-09-25 2020-09-25
US63/083,834 2020-09-25
US202063107196P 2020-10-29 2020-10-29
US63/107,196 2020-10-29
US202163238483P 2021-08-30 2021-08-30
US63/238,483 2021-08-30
PCT/US2021/051957 WO2022067039A1 (en) 2020-09-25 2021-09-24 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
AU2021347349A1 true AU2021347349A1 (en) 2023-06-08

Family

ID=78179552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021347349A Pending AU2021347349A1 (en) 2020-09-25 2021-09-24 Pharmaceutical formulation

Country Status (10)

Country Link
US (1) US20230338283A1 (https=)
EP (1) EP4216956A1 (https=)
JP (1) JP2023542701A (https=)
KR (1) KR20230074536A (https=)
AU (1) AU2021347349A1 (https=)
CA (1) CA3196829A1 (https=)
IL (1) IL301596A (https=)
MX (1) MX2023003431A (https=)
TW (1) TW202228691A (https=)
WO (1) WO2022067039A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2561132C2 (ru) 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
FI3307271T3 (fi) 2015-06-11 2023-10-17 Agios Pharmaceuticals Inc Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
JP7275130B2 (ja) * 2017-11-22 2023-05-17 アジオス ファーマシューティカルズ， インコーポレイテッド Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態

Also Published As

Publication number Publication date
US20230338283A1 (en) 2023-10-26
MX2023003431A (es) 2023-05-12
WO2022067039A1 (en) 2022-03-31
CA3196829A1 (en) 2022-03-31
KR20230074536A (ko) 2023-05-30
JP2023542701A (ja) 2023-10-11
IL301596A (en) 2023-05-01
TW202228691A (zh) 2022-08-01
EP4216956A1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
Rodríguez-Pombo et al. Paediatric clinical study of 3D printed personalised medicines for rare metabolic disorders
US6335361B1 (en) Method of treating benign forgetfulness
Nance Spinal muscular atrophy
TWI875681B (zh) 高劑量戊苯那嗪（valbenazine）調配物及組合物、方法以及相關套組
JP7093907B2 (ja) レベチラセタムの持続放出性医薬組成物
US20200170965A1 (en) Methods of treating doose syndrome using fenfluramine
Lechin et al. Neuropharmacologic treatment of bronchial asthma with the antidepressant tianeptine: A double‐blind, crossover placebo‐controlled study
US20260097054A1 (en) Arginine silicate inositol for improving cognitive function
JP2021523130A (ja) 電位依存性カリウムチャネル開口薬のバイオアベイラビリティー及び曝露を高める方法
CN120379676A (zh) 治疗阿拉杰里综合征(algs)
CN109982686A (zh) 普利多匹定用于治疗rett综合征的用途
US20260076986A1 (en) A combination of scyllo-inositol and flavones
US20230338283A1 (en) Pharmaceutical formulation
US20250073318A1 (en) Mitapivat therapy and modulators of cytochrome p450
CN116568281A (zh) 药物制剂
US20070298057A1 (en) Composition and method for modulating addictive behaviors
WO2019094434A1 (en) Therapeutic combination for treatment of cerebellar ataxia
Kwinta et al. Pathology and treatment methods in pantothenate kinase-associated neurodegeneration
Ross et al. P1498: initial data from the beacon trial: a phase 2, randomized, open-label trial of bitopertin in erythropoietic protoporphyria
Hughes et al. Pharmacokinetics and Pharmacodynamics of Levetiracetam in Neonatal Seizures: What We Still Need to Know
Cederwall An Evaluation of Non-pharmacological, Non-invasive Complementary Interventions for Reducing Parkinson's Disease Symptom Severity and Rate of Disease Progression
Bloom et al. The effect of dietary tartrazine on brain dopamine and the behavioral symptoms of attention deficit hyperactivity disorder
Urraca et al. An 8q21 deletion in a patient with comorbid psychosis and mental retardation
CN117898437A (zh) 一种改善脑部健康状况和/或改善神经相关不适状况的营养素组合物及其产品和应用
MANERIKAR et al. Pharmaceutico-analytical Study of Lakshadi Guggulu and Pravalyukta Lakshadi Guggulu and their Comparative In-vivo Evaluation of Anti-osteoporotic Activity: A Research Protocol of Experimental Study.